Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 23:S1535-6108(25)00316-2.
doi: 10.1016/j.ccell.2025.07.010. Online ahead of print.

Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma

Affiliations

Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma

Nicholas J Salgia et al. Cancer Cell. .

Abstract

Renal cell carcinoma with sarcomatoid features (sRCC) is a highly aggressive tumor type yet preferentially responds to immune checkpoint blockade (ICB). To better understand microenvironmental mediators of this paradoxical immune sensitivity, we performed single-cell analyses of human sRCC tumors compared against clear cell RCC (ccRCC), with validation spatially and in bulk transcriptomic datasets totaling over 3,000 RCC tumors. We describe a robust immune network in sRCC using these orthogonal approaches: tumor-infiltrating T cells in sRCC are more activated, and subsequently exhausted, while being enriched for CXCL13 expression. Congruently, tertiary lymphoid structures are pervasive in sRCC, paralleling functional enrichment of humoral immune activity. Tumor clone analysis revealed increased iron-associated programs in sRCC, presenting a potential vulnerability. We furthermore leveraged the paradoxical biology of sRCC to derive a genomic dedifferentiation signature (GDS) that, while negatively prognostic, identifies patients most likely to benefit from ICB across cohorts and tumor types.

Keywords: anti-tumor immunity; humoral immunity; immune checkpoint blockade; immune repertoire; predictive biomarker; renal cell carcinoma; sarcomatoid; single cell RNA sequencing; spatial transcriptomics; tertiary lymphoid structure.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.C. is an employee of Moderna, Inc. M.M. is an employee of Thermo Fisher Scientific. K.H.E. is an employee of Eikon Therapeutics, Inc. A.J.R.M. reports consulting for Radiant Biotherapeutics, Inc. and serves on the scientific advisory board of 9Bio Therapeutics, Inc. S.K.P. reports participation in Speakers’ Bureau for MJH Life Sciences, IntrinsiQ Specialty Solutions, Inc., and Peerview, and has received travel, accommodations, and expenses from Crispr Therapeutics AG, Ipsen Biopharmaceuticals, Inc., and Exelixis, Inc.

Similar articles

References

    1. Shen C, and Kaelin WG Jr. (2013). The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 23, 18–25. 10.1016/j.semcancer.2012.06.001. - DOI - PMC - PubMed
    1. Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, and Hakimi AA (2020). Sarcomatoid renal cell carcinoma: biology, natural history and management. Nature Reviews Urology 17, 659–678. 10.1038/s41585-020-00382-9. - DOI - PMC - PubMed
    1. Conant JL, Peng Z, Evans MF, Naud S, and Cooper K (2011). Sarcomatoid renal cell carcinoma is an example of epithelial–mesenchymal transition. Journal of Clinical Pathology 64, 1088–1092. 10.1136/jclinpath-2011-200216. - DOI - PubMed
    1. Jones TD, Eble JN, Wang M, MacLennan GT, Jain S, and Cheng L (2005). Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. Cancer 104, 1195–1203. 10.1002/cncr.21288. - DOI - PubMed
    1. Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu L-F, Leng N, Abbas AR, et al. (2020). Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell 38, 803–817.e804. 10.1016/j.ccell.2020.10.011. - DOI - PMC - PubMed

LinkOut - more resources